Cortisys is building an automated, standalone neuromodulation platform to deliver mental healthcare at scale. Their system uses multi‑locus Transcranial Magnetic Stimulation (mTMS) to stimulate multiple critical brain networks non‑invasively, drug‑free, and with minimal side effects. By automating complex setup and positioning steps that currently require specialized personnel, Cortisys unlocks neuromodulation for many more patients.

Today, neurological and psychiatric conditions affect roughly 4% of the global population and are a leading cause of disability. Legacy TMS workflows are manual, slow, and poorly individualized: while 60–80% of patients respond, only 30–60% achieve meaningful symptom relief. Cortisys mTMS platform is designed to treat depression and other disorders as network diseases, enabling AI‑ready, individualized stimulation protocols that can be delivered more efficiently and consistently across sites. The company is backed by +40 technical and experimental publications, 4 patent families, and 5 deployments across multiple countries (Finland, Germany, Italy, and Brazil) and has just delivered one system to its first paying customer.